Seminars in nuclear medicine最新文献_第10页

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2026-01-01 Epub Date: 2026-01-13 DOI: 10.1053/j.semnuclmed.2025.12.004

引用次数: 0

A Review of Advances in Lung Function Imaging and Its Applications for Functional Lung Avoidance in Radiation Therapy 肺功能影像学研究进展及其在放射治疗中肺功能回避的应用。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-11-01 Epub Date: 2025-09-26 DOI: 10.1053/j.semnuclmed.2025.09.002

Zhi Chen , Zihan Li , Yu-Hua Huang , Tianyu Xiong , Xinzhi Teng , Bing Li , John Kipritidis , Paul J. Keall , Joseph M. Reinhardt , Hong Ge , Ge Ren , Jing Cai

{"title":"A Review of Advances in Lung Function Imaging and Its Applications for Functional Lung Avoidance in Radiation Therapy","authors":"Zhi Chen , Zihan Li , Yu-Hua Huang , Tianyu Xiong , Xinzhi Teng , Bing Li , John Kipritidis , Paul J. Keall , Joseph M. Reinhardt , Hong Ge , Ge Ren , Jing Cai","doi":"10.1053/j.semnuclmed.2025.09.002","DOIUrl":"10.1053/j.semnuclmed.2025.09.002","url":null,"abstract":"<div><div>Lung function imaging, with a specific focus on quantifying ventilation and perfusion, has gained increasing recognition within the field of functional lung avoidance radiation therapy (FLART), a technique that incorporates functional information to minimize radiation exposure to healthy lung tissue. This review critically analyzes multiple categories of clinical imaging modalities, including nuclear medicine imaging, computed tomography, and magnetic resonance imaging, which can assess the spatial distribution of lung functions. Each modality presents unique strengths in providing valuable information for FLART, yet they also have their limitations, which are detailed in this review. Furthermore, we discuss the current challenges limiting the broader implementation of lung function imaging and FLART in clinical practice. Future research directions and potential solutions are also outlined, to enable lung function imaging to play a more significant role in FLART, leading to personalized lung cancer management and improved patient outcomes.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 6","pages":"Pages 1046-1057"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145177979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mucin-Targeted Antibodies for Ovarian Cancer 用于卵巢癌的黏液蛋白靶向抗体

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-11-01 Epub Date: 2025-07-03 DOI: 10.1053/j.semnuclmed.2025.06.007

Shaniqua A. Lawson, Jason S. Lewis

{"title":"Mucin-Targeted Antibodies for Ovarian Cancer","authors":"Shaniqua A. Lawson, Jason S. Lewis","doi":"10.1053/j.semnuclmed.2025.06.007","DOIUrl":"10.1053/j.semnuclmed.2025.06.007","url":null,"abstract":"<div><div><span><span>Ovarian cancer remains a leading cause of </span>gynecologic cancer<span><span><span> mortality, driven in part by late-stage diagnoses and high recurrence rates. Among emerging molecular targets, mucins—highly glycosylated transmembrane glycoproteins overexpressed and aberrantly glycosylated in epithelial ovarian cancers—have garnered increasing interest for both imaging and therapeutic strategies. This review highlights the expression profiles and clinical implications of key mucins (MUC1, MUC16) and evaluates antibody-based modalities that leverage these targets for enhanced tumor detection and treatment. We discuss the current landscape of therapeutic strategies, including </span>monoclonal antibodies<span>, antibody-drug conjugates, bispecific antibodies<span>, and radioimmunotherapy, with emphasis on recent preclinical and clinical advances. We also examine the role of mucin-targeted antibodies in imaging and the integration of theranostic platforms. Key challenges such as antigen heterogeneity, </span></span></span>immunogenicity, and tumor penetration are addressed, along with future directions for optimizing mucin-directed therapies. Together, these efforts underscore the ever-expanding potential of mucin-targeted </span></span>immunotherapy to improve outcomes for patients with ovarian cancer.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 6","pages":"Pages 955-965"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding the Horizon of Targeted Radionuclide Therapy: Immunotherapy Combinations and FAP-Targeted Approaches 扩大靶向放射性核素治疗的视野：免疫治疗组合和fap靶向方法。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1053/j.semnuclmed.2025.08.003

Ayça Arçay Öztürk, Wendy Delbart, Patrick Flamen

{"title":"Expanding the Horizon of Targeted Radionuclide Therapy: Immunotherapy Combinations and FAP-Targeted Approaches","authors":"Ayça Arçay Öztürk, Wendy Delbart, Patrick Flamen","doi":"10.1053/j.semnuclmed.2025.08.003","DOIUrl":"10.1053/j.semnuclmed.2025.08.003","url":null,"abstract":"<div><div>Targeted radionuclide therapy (TRT) has emerged as a promising cancer treatment modality and is increasingly recognized as an immunomodulatory tool, similar to external beam radiotherapy (EBRT). Both forms of radiation can reshape the tumor immune microenvironment, providing a rationale for their combination with immune checkpoint inhibitors (ICIs) to harness synergistic effects while mitigating immunosuppressive mechanisms. Outcomes of such combinations depend on radiation dose/fractionation, treatment sequencing, target selection, and the choice of immunotherapeutic/radiopharmaceutical agents. Among novel TRT strategies, fibroblast activation protein-TRT (FAP-TRT) stands out for its targeting of cancer-associated fibroblasts (CAFs), key components of the tumor stroma involved in immune evasion and therapy resistance. Unlike conventional TRTs that directly target tumor cells, FAP-TRT acts on CAFs, potentially modulating the tumor microenvironment to enhance the immunomodulatory effects of radiation. This review examines the immunological effects of radiation—via EBRT or TRT-and the rationale for combining TRT with ICIs. We highlight preclinical and clinical studies demonstrating both the synergistic potential and context-specific limitations of TRT–ICI combinations. Emphasis is placed on the emerging role of FAP-TRT in remodeling the tumor microenvironment, converting “cold” tumors into “hot” phenotypes, and enhancing immune infiltration. Preclinical models show synergy between FAP-TRT and ICIs, but challenges remain, including clarifying FAP-TRT’s effects on CAF subpopulations, optimizing radiopharmaceutical design, and addressing shared issues with TRT/EBRT–ICI combinations, such as dosing, sequencing, and target selection. The integration of TRT and immunotherapy—particularly FAP-TRT combinations—offers a compelling avenue for precision oncology and warrants further translational and clinical investigation.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 6","pages":"Pages 999-1010"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145131881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[177Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review [177]卢- fapi放射治疗在实体瘤中的应用前景。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-11-01 Epub Date: 2025-07-04 DOI: 10.1053/j.semnuclmed.2025.06.010

Akram Al-Ibraheem , Ahmed Saad Abdlkadir , Saad Ruzzeh , Marwah Abdulrahman , Serin Moghrabi , Rawa Ahmed , Hongcheng Shi , Fadi Khreish , Michael C. Kreissl , Rula Amarin , Kamal Al-Rabi , Asem Mansour , Hikmat Abdel-Razeq

{"title":"[177Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review","authors":"Akram Al-Ibraheem , Ahmed Saad Abdlkadir , Saad Ruzzeh , Marwah Abdulrahman , Serin Moghrabi , Rawa Ahmed , Hongcheng Shi , Fadi Khreish , Michael C. Kreissl , Rula Amarin , Kamal Al-Rabi , Asem Mansour , Hikmat Abdel-Razeq","doi":"10.1053/j.semnuclmed.2025.06.010","DOIUrl":"10.1053/j.semnuclmed.2025.06.010","url":null,"abstract":"<div><div>[<sup>177</sup><span>Lu]Lu-FAPI, a novel and innovative radioligand<span><span> targeting fibroblast activation protein (FAP), has rapidly emerged as a powerful therapeutic strategy for difficult-to-treat solid malignancies. FAP is highly expressed in cancer-associated fibroblasts (CAFs) across a broad spectrum of solid malignancies, thereby providing a valuable therapeutic target for novel </span>radiopharmaceuticals. To date, a growing body of preliminary studies has explored the therapeutic potential of [</span></span><sup>177</sup><span>Lu]Lu-FAPI in oncology<span>, with numerous ongoing clinical trials currently recruiting patients to substantiate its evolving prospects. This comprehensive review critically synthesizes current clinical evidence on [</span></span><sup>177</sup><span>Lu]Lu-FAPI radioligand therapy (RLT), outlining its available formulations, therapeutic efficacy, safety profile, recent advancements, challenges, and emerging applications across diverse tumor types. [</span><sup>177</sup>Lu]Lu-FAPI has shown considerable promise as an effective and relatively safe theranostic agent, with particular advantages in combination therapy approaches. Nevertheless, larger, well-controlled clinical studies are essential to establish its long-term efficacy and safety profile. Despite current limitations, this review underscores the emerging role of [<sup>177</sup>Lu]Lu-FAPI in oncological care, with growing relevance to personalized oncology strategies, and calls for further investigation to refine its clinical integration and maximize patient-specific outcomes.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 6","pages":"Pages 988-998"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiolabeled Antibody–Drug Conjugates in the Treatment of Solid Tumors 放射标记抗体-药物偶联物在实体肿瘤治疗中的应用。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-11-01 Epub Date: 2025-09-12 DOI: 10.1053/j.semnuclmed.2025.08.002

Ismaheel O. Lawal , Sofiullah Abubakar , Honest Ndlovu , Aisha Ismaila , Mike M. Sathekge

{"title":"Radiolabeled Antibody–Drug Conjugates in the Treatment of Solid Tumors","authors":"Ismaheel O. Lawal , Sofiullah Abubakar , Honest Ndlovu , Aisha Ismaila , Mike M. Sathekge","doi":"10.1053/j.semnuclmed.2025.08.002","DOIUrl":"10.1053/j.semnuclmed.2025.08.002","url":null,"abstract":"<div><div>Antibody-drug conjugates (ADCs) utilize monoclonal antibodies (mAbs) that target tumor-specific antigens to deliver potent cytotoxic chemotherapy payloads to the tumor, while sparing normal tissues. The chemotherapy agents employed in ADCs are very potent, causing a tumoricidal effect at low drug concentrations. Several ADCs have been approved for the treatment of different solid tumors over the last decade following the superior efficacy and safety they demonstrated above standard-of-care treatment modalities in several clinical trials. Despite their efficacy, some patients do not respond to treatment with ADCs, as objective response rate typically range from 30% to 50%, and as low as 20% in some instances. Some patients who initially respond to treatment develop acquired resistance during their treatment, necessitating strategies to improve response rates and overcome treatment resistance. Radiation from radionuclides, with their ability to evoke a synergistic antitumor effect when used in combination with cytotoxic chemotherapy and induce a tumoricidal effect in tumor cells remote from the tumor they are bound to (crossfire effect), has the potential to improve the outcomes of ADC treatment. An expanding body of evidence, reporting the successful radiolabeling of established and experimental ADCs, is emerging in the literature. These studies have demonstrated improved antitumor effect of radiolabeled ADC relative to cold ADC, paving the way for further exploration, including in clinical settings.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 6","pages":"Pages 889-902"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Dosimetry and Imaging for 203Pb and 212Pb Radiotheranostics 203Pb和212Pb放射治疗学剂量学与影像学研究进展。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-11-01 Epub Date: 2025-10-08 DOI: 10.1053/j.semnuclmed.2025.09.006

Keamogetswe Ramonaheng , Milani Qebetu , Kaluzi Banda , Pryaska Goorhoo , Khomotso Legodi , Sipho Mdanda , Sandile Sibiya , Yonwaba Mzizi , Honest Ndlovu , Joseph Kabunda , Mengdie Yang , Kuangyu Shi , Mike Sathekge

{"title":"Advances in Dosimetry and Imaging for 203Pb and 212Pb Radiotheranostics","authors":"Keamogetswe Ramonaheng , Milani Qebetu , Kaluzi Banda , Pryaska Goorhoo , Khomotso Legodi , Sipho Mdanda , Sandile Sibiya , Yonwaba Mzizi , Honest Ndlovu , Joseph Kabunda , Mengdie Yang , Kuangyu Shi , Mike Sathekge","doi":"10.1053/j.semnuclmed.2025.09.006","DOIUrl":"10.1053/j.semnuclmed.2025.09.006","url":null,"abstract":"<div><div>Targeted alpha therapy (TAT) with <sup>212</sup>Pb is rapidly emerging as a potent modality for cancer treatment due to the high linear energy transfer and short path length of α-particles, which enable precise tumor cell killing while sparing surrounding healthy tissue. Its elementally identical theranostic partner, <sup>203</sup>Pb, functions as a γ-emitting surrogate for quantitative SPECT imaging, providing essential information for patient-specific dosimetry and treatment planning. Advances in SPECT imaging, ranging from NaI(Tl)-based dual-head systems to CZT multi-detector gamma cameras, have enhanced spatial resolution, quantitative accuracy, and lesion detectability, enabling rapid patient scanning and improved activity quantification for dosimetry. Clinical dosimetry workflows that integrate serial <sup>203</sup>Pb SPECT/CT acquisitions, pharmacokinetic modeling, and image-based activity quantification facilitate reliable generation of time–activity curves and absorbed dose estimates. Organ-level and voxel-based dosimetry, combined with advanced reconstruction and microdosimetric modeling, further refine dose calculations, supporting individualized therapy planning. Collectively, these developments highlight the translational potential of the <sup>203</sup>Pb/<sup>212</sup>Pb theranostic pair. The aim of this review is to provide a comprehensive assessment of <sup>212</sup>Pb-TAT, encompassing clinical applications, surrogate imaging with <sup>203</sup>Pb, gamma camera performance, dosimetry workflows, and predictive activity quantification, illustrating how these advances collectively enable quantitative, patient-specific, and theranostic-integrated radionuclide therapy.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 6","pages":"Pages 1011-1031"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to ‘18F-FDG PET for Dementia Evaluation: Co-pathologies, New Diseases, and Its Roles in The Era of Anti-Amyloid Treatment’ [Seminar in Nuclear Medicine volume 55 (2025):526 –537/Article number YSNUC_51208] “18F-FDG PET用于痴呆评估：共病理，新疾病及其在抗淀粉样蛋白治疗时代的作用”的勘误表[核医学研讨会卷55(2025):526 -537/文章编号YSNUC_51208]。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-11-01 Epub Date: 2025-09-25 DOI: 10.1053/j.semnuclmed.2025.09.001

Tanyaluck Thientunyakit , Weerasak Muangpaisan , Satoshi Minoshima

引用次数: 0

CD70-Targeted Radiotheranostics: Now and Future cd70靶向放射治疗：现在与未来。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-11-01 Epub Date: 2025-09-18 DOI: 10.1053/j.semnuclmed.2025.08.001

Binyu Shi , Xinyuan Zhou , Junjun Zhou , Gang Huang , Jianjun Liu , Jin Zhang , Weijun Wei

引用次数: 0

GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy GRPR在转移性癌症中的表达：GRPR放射配体治疗的潜在应用综述。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-11-01 Epub Date: 2025-08-11 DOI: 10.1053/j.semnuclmed.2025.07.003

Aurélien Callaud , Heying Duan , Elif Hindié , Clément Morgat , Andrei Iagaru

{"title":"GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy","authors":"Aurélien Callaud , Heying Duan , Elif Hindié , Clément Morgat , Andrei Iagaru","doi":"10.1053/j.semnuclmed.2025.07.003","DOIUrl":"10.1053/j.semnuclmed.2025.07.003","url":null,"abstract":"<div><div>Gastrin-Releasing Peptide Receptor (GRPR) represents a promising molecular target for radionuclide therapy (TRT) across a variety of malignancies due to its overexpression in several tumor types, including prostate, breast, lung, melanoma, cervix, neuroblastoma, head and neck, and colon cancers. While expression patterns vary—with high GRPR expression notably observed in cervix and neuroblastoma cancers—tumor heterogeneity and metastatic profiles remain challenges for patient selection and therapy optimization. Recent advances in GRPR-targeted radiopharmaceutical development have focused on overcoming peptide instability and enhancing tumor uptake, exemplified by novel compounds such as AMTG with improved proteolytic resistance and albumin binding domains to extend circulatory half-life. Furthermore, innovative radionuclides like terbium-161, lead-212, copper-67, cobalt-58 m, and arsenic-77 offer enhanced therapeutic potential beyond the current standard of lutetium-177 through favorable decay characteristics including Auger electron emission and alpha-particle therapy. Preclinical and early clinical studies demonstrate encouraging tumor targeting and therapeutic efficacy with manageable toxicity profiles, particularly in prostate and cervix cancers. However, further investigation into GRPR expression heterogeneity, metastatic distribution, and safety is necessary to refine patient stratification and maximize clinical benefit. This evolving landscape positions GRPR-TRT as a versatile and potent approach, with the potential to expand targeted radionuclide therapy to a broader range of malignancies and improve outcomes in advanced cancers with limited treatment options.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 6","pages":"Pages 937-946"},"PeriodicalIF":5.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0